Evidence map›Paper›PMID 28389626›Full record

SynthesisOncotarget2017

Metabolomics for biomarker discovery in the diagnosis, prognosis, survival and recurrence of colorectal cancer: a systematic review.

Fan Zhang, Yuanyuan Zhang, Weiwei Zhao, Kui Deng, Zhuozhong Wang, Chunyan Yang, Libing Ma, Margarita S Openkova, Yan Hou, Kang Li

Open access · diamondAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Tumor-exosomal miR-205-5p as a diagnostic biomarker for colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Fan ZhangDepartment of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, P.R. China.
Yuanyuan ZhangDepartment of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, P.R. China.
Weiwei ZhaoDepartment of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, P.R. China.
Kui DengDepartment of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, P.R. China.
Zhuozhong WangDepartment of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, P.R. China.
Chunyan YangDepartment of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, P.R. China.
Libing MaDepartment of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, P.R. China.
Margarita S OpenkovaHarbin Medical University, Harbin, P.R. China.
Yan HouDepartment of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, P.R. China.
Kang LiDepartment of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, P.R. China.
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) remains an incurable disease. There are no effective noninvasive techniques that have achieved colorectal cancer (CRC) diagnosis, prognosis, survival and recurrence in clinic. To investigate colorectal cancer metabolism, we perform an electronic literature search, from 1998 to January 2016, for studies evaluating the metabolomic profile of patients with CRC regarding the diagnosis, recurrence, prognosis/survival, and systematically review the twenty-three literatures included. QUADOMICS tool was used to assess the quality of them. We highlighted the metabolism perturbations based on metabolites and pathway. Metabolites related to cellular respiration, carbohydrate, lipid, protein and nucleotide metabolism were significantly altered in CRC. Altered metabolites were also related to prognosis, survival and recurrence of CRC. This review could represent the most comprehensive information and summary about CRC metabolism to date. It certificates that metabolomics had great potential on both discovering clinical biomarkers and elucidating previously unknown mechanisms of CRC pathogenesis.

Indexed as

Biomarkers, TumorColorectal NeoplasmsFemaleHumansMetabolomicsNeoplasm Recurrence, LocalPrognosisSurvival AnalysisBiomarkers, TumorbiomarkersCRCmetabolomicspathwaysystematic review

Identifiers

PMID28389626
PMCPMC5471069
OpenAlexW2599861251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.